A Randomized Open-Label Multi-Institution Phase II Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients With Advanced Hepatocellular Carcinoma (HCC).

Trial Profile

A Randomized Open-Label Multi-Institution Phase II Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients With Advanced Hepatocellular Carcinoma (HCC).

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Oct 2015

At a glance

  • Drugs Bevacizumab (Primary) ; Erlotinib (Primary) ; Sorafenib
  • Indications Liver cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Oct 2015 Planned primary completion date changed from 1 Jun 2015 to 1 Jun 2016, as reported by ClinicalTrials.gov.
    • 09 Dec 2014 Planned primary completion date changed from 1 Dec 2013 to 1 Jun 2015 as reported by ClinicalTrials.gov.
    • 09 Dec 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top